{"id":"NCT01998477","sponsor":"Novartis Vaccines","briefTitle":"A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications","officialTitle":"A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (TIVc) or in Embryonated Eggs (TIV), in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2013-11-29","resultsPosted":"2017-04-21","lastUpdate":"2017-04-21"},"enrollment":430,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"TIVc","otherNames":[]},{"type":"BIOLOGICAL","name":"TIV","otherNames":[]}],"arms":[{"label":"TIVc","type":"EXPERIMENTAL"},{"label":"TIV","type":"ACTIVE_COMPARATOR"}],"summary":"The study is designed to evaluate the safety of TIVc or TIV vaccine in children 3 to \\< 18 years of age who are at risk of complications of influenza disease due to underlying diseases.","primaryOutcome":{"measure":"Number of Subjects Reporting Solicited Adverse Events (AEs) Following Vaccination With Either TIVc or TIV by Overall Age Group","timeFrame":"Day 1 through Day 7 post injection 1 and Day 29 through Day 35 post injection 2","effectByArm":[{"arm":"TIVc _inj 1 (3 to <18 Years)","deltaMin":149,"sd":null},{"arm":"TIVc_inj 2 (3 to <18 Years)","deltaMin":41,"sd":null},{"arm":"TIV_inj 1 (3 to <18 Years)","deltaMin":89,"sd":null},{"arm":"TIV_inj 2 (3 to <18 Years)","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":16,"countries":["Italy","Spain"]},"refs":{"pmids":["27343983"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":278},"commonTop":["INJECTION SITE PAIN","HEADACHE","INJECTION SITE INDURATION","INJECTION SITE ERYTHEMA","PYREXIA"]}}